Detoxification and Healthy Inflammatory Response Arrive in Time for the Holidays and Well Being in the New Year
Cymbiotika, a leading dietary supplement brand known for creating pure, clinically backed supplements, announced today the release of Liposomal Sulforaphane Matrix to support wellness through detoxification and healthy inflammation response. Sourced and tested in the US, Cymbiotika's gluten-free, vegan, keto, and sugar-free Liposomal Sulforaphane Matrix is differentiated by zero synthetic ingredients and a patented Liposomal/Micelle delivery system, which ensures maximum absorption, guaranteeing nutrients make it into the cell so that nothing is wasted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201218005122/en/
(Photo: Business Wire)
Sulforaphane is an extremely powerful phytochemical found in broccoli sprouts and all cruciferous vegetables such as cauliflower, cabbage, kale, watercress, bok choy and mustard greens. Research shows that this compound plays a critical role in cellular detoxification by neutralizing toxins and canceling out free radicals as well as calming inflammation in the body.
"Our environment, from the air we breathe to the food we eat, is filled with toxins that can negatively impact our health," said Cymbiotika Founder Chervin Jafarieh. "Our Liposomal Sulforaphane Matrix works to activate cellular detoxification by inducing the three primary phases of detoxification. It effectively encourages every step required to remove a toxin from the body. In fact, sulforaphane has been discovered to be the most potent inducer of Phase II enzymes ever identified. Phase II detoxification is a process in which the liver uses one of two major enzyme pathways to remove a toxic substance from the body, such as known carcinogens in our food supply like glyphosate."
Cymbiotika’s CEO/Managing Partner, Shahab Elmi, added, "Throughout this challenging year, we have brought products to market to help improve immunity, physical response to stress, and overall well-being. We are excited to introduce Cymbiotika’s Liposomal Sulforaphane Matrix as our customers look to detox from 2020 and focus on a fresh year and continued efforts to optimize their health."
Cymbiotika utilizes a patented delivery mechanism that converts sulforaphane from an inactive state to a more bioavailable active form. This is achieved through enzymatic activation using Myrosinase combined with Micellular Liposomal encapsulation.
Cymbiotika’s Liposomal Sulforaphane Matrix contains sulforaphane, glucosinolates, and chlorophyllin—phytochemicals that have been extensively studied for their profound effects on various areas of health including healthy cell replication and inflammatory response, hair regrowth, cognitive health and brain function, and improved digestive health. Cymbiotika’s Liposomal Sulforaphane Matrix is an easy to use liquid; no capsules, powders or tablets to swallow. Enjoy directly from the pouch or add to water, smoothies, your favorite warm beverage or treat.
One box of (30) 10ml pouches retails for $78 and is now available for purchase through the Cymbiotika website. Cymbiotika’s Liposomal Sulforaphane Matrix is also available in Cymbiotika’s Immune Nutrition Bundle (with Elderberry and D3K2) and Cellular Cleanse Bundle (with Regenesis, B12 and Charcoal).
Cymbiotika is an innovative wellness brand based in San Diego. With the motto, "Your body deserves the best," Cymbiotika is driven by the higher purpose of inspiring everyday people to reclaim control of their lives and achieve their optimal health. Founded in 2018, Cymbiotika uses the most advanced bioavailable absorption technology and sources only the highest quality plant-based nutrients to resolve specific nutritional deficiencies and support healthy aging, detoxification and longevity. Cymbiotika never uses synthetics, GMOs, fillers, chemicals, preservatives, additives or sugars in its products. For more information, visit www.cymbiotika.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005122/en/